Introduction
Active myocarditis (AM) is an inflammatory disease of the myocardium, diagnosed by established histological 1 , immunological and immunohistochemical criteria 2 . Heterogeneity of clinical manifestation is a peculiar feature of AM, which may variably present with recent onset heart failure (HF), arrhythmias, chest pain or a concurrence of these elements 3 . Similarly, natural history of AM is highly variable, ranging from full recovery to development of dilated cardiomyopathy or sudden cardiac death 3 . The prognostic stratification is critical in the management of AM. However, several studies including heterogeneous populations evaluated the prognostic values of different clinical and instrumental parameters in the mid-term risk assessment and reported conflicting conclusions 4, 5, 6 . Thus, currently there is no accordance on early independent long-term prognostic predictors for AM.
Our study describes the long-term natural history of a large sample of patients with AM diagnosed by endomyocardial biopsy (EMB), looking for accessible and valid early predictors of long-term prognosis. In particular, we estimated the prognostic role of early revaluation.
Methods

Study population
From 1981 to 2009, 82 patients with EMB proven AM were consecutively enrolled in the Trieste Heart Muscle Disease Registry. Informed consent was obtained from all subjects under the institutional review board policies of the Trieste Hospital administration. At baseline, all patients underwent a careful clinical evaluation, laboratory testing and echocardiographic assessment.
Right ventricular catheterization was performed in presence of left ventricular (LV) dysfunction
(LV ejection fraction -LVEF -<50%). All patients with cardiovascular risk factors, or older than 35, underwent selective coronary angiography to exclude coronary artery disease. assessment and reported conflicting conclusions 4, 5, 6 . Thus, currently there is no ac ac cco o ord rd dan an ance ce ce o o on n early independent long-term prognostic predictors for AM.
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by guest on April 12, 2017 http://circ.ahajournals.org/ Downloaded from AM was defined as "peripartum" when occurring during the last month of pregnancy or within 5 months after delivery.
Fulminant myocarditis was defined as the rapid onset of severe HF distinctly identifiable within the four weeks before the time of enrolment, associated with severe LV or biventricular dysfunction, hemodynamic instability and need for advanced pharmacological or mechanical circulatory assistance 7 .
Laboratory testing consisted in: 1) evaluation of inflammation and myocytolysis markers, Cardiac magnetic resonance (CMR) and brain natriuretic peptide (BNP) testing were systematically performed since 2008 in patients with AM; given the small number of subjects that underwent these evaluations, CMR and BNP data were not included in the present analysis.
Endomyocardial biopsy and sample analysis
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Study design and outcome measure
All patients (except one, who refused the examination) were followed with a scheduled revaluation at 6 (3 to 9) months from baseline in our HF Outpatient Clinic. Further assessments were planned according to the clinical and instrumental status of each patient.
The study outcome measure was long-term heart transplantation (HTx)-free survival.
Patients were categorized in three groups according to the main pattern of disease onset: (last check-date of status for alive patients) or the date of death or HTx.
Statistical Analysis
Summary statistics of clinical and instrumental variables were expressed as mean ± standard deviation or median and first-third quartile or percentages, as appropriate.
Continuous variables were compared between groups by the Analysis of Variance (ANOVA), using the Brown-Forsythe statistic when the assumption of equal variances did not hold 10, 11 , whereas for discrete variables the Fisher's exact test was applied, with a Monte Carlo approximation to compute the p values when appropriate.
To define the improvement/normality criterion a grid of different cut-off values for LVEF variation between baseline and 6 months were 'a priori' selected and compared by means of the Receiver-Operating Characteristic analysis for the end-point death/HTx, and the best one in terms of Area under the Curve was selected (Supplemental Table 1 To predict the improvement/normality at 6 months (LVEF increase > 20 percentage points, or LVEF 50%), a univariable screening of all clinical-laboratory baseline parameters of patients was initially made (estimating univariable logistic regression models variable by variable), followed by the application of a backward elimination based on likelihood ratio testing to the list of selected parameters (i.e., with p<0.1) at the univariable procedure, in order to estimate the multivariable logistic regression model.
Survival curves were calculated according to the Kaplan-Meier method, and the comparison between curves was carried out with the Log-Rank test.
Univariable Cox proportional hazards models were applied to find predictors of the endpoint. Multivariable Cox models were then estimated by means of a backward elimination based on likelihood ratio testing starting from the list of variables derived at the previous univariable screening.
The prognostic accuracy of the estimated survival models was estimated by using
Receiver-Operating Characteristic analysis 12 : predicted probabilities of survival estimated by the baseline model were compared to the predicted probabilities of survival estimated by the 6 months model, re-estimating also the baseline model with a follow up starting at 6 months for the survived patients. All results were considered statistically significant when p<0.05.
The entire analysis was performed using the SPSS package, version 13.0 (SPSS Inc., Chicago, Illinois) and R statistical software version 2.7.2.
Results
Study Population
Baseline characteristics of study patients are summarized in Table 1 . Patients were young (age 38±16 years) and predominantly males. The interval between the onset of cardiac symptoms and endpoint. Multivariable Cox models were then estimated by means of a backward rd d e e eli limi mi mina na nati ti tion on o based on likelihood ratio testing starting from the list of variables derived at the previous un niv iv var ar ria ia iabl bl ble e e sc sc creen en enin in i g.
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Re Rece ce c iv iv iver er-O -O Ope pe p ra rat ti ing ng ng C C Cha ha ara ract cte er eris is sti ti tic c c a an ana al lys ys ysis is is hospitalization was shorter than one month in 75% of patients and only 15% of subjects presented with left branch bundle block. On EMB, 75 patients (91%) had lymphocytic myocarditis; despite extensive investigation, in most cases (71%) the precise etiology could not be established by serological testing.
Patient characteristics according to the pattern of disease onset at enrolment and at 6 months are described in Table 1 . Among the three groups, patients with HF presented more frequently LV dysfunction and enlarged left atrium and ventricle. The interval between the onset of cardiac symptoms and hospitalization was significantly longer in patients with HF, compared to the other groups; however, it was shorter than 2 months in 75% of HF patients.
Among patients with arrhythmic onset, 10 presented with tachyarrhythmias (6 with ventricular fibrillation/flutter or sustained ventricular tachycardia; 1 with frequent symptomatic ventricular premature beats; 3 with supraventricular arrhythmias) and 10 presented with bradyarrhythmias (2 with II degree atrioventricular block and 8 with III degree atrioventricular block).
At 6 months 41 subjects (53%) satisfied the LVEF improvement/normality criterion.
Immunosuppressive therapy was administered to 56% of the patients of the entire cohort. In comparison with the remaining patients, they were characterized by a more severe functional impairment (NYHA III-IV 67% vs 33%, p=0.066), a larger LV end-diastolic diameter (37 [33- Among patients with arrhythmic onset, 10 presented with tachyarrhythmi mia a as ( (6 6 (28%) patients died and 7 (9%) underwent HTx. HF was the most prevalent cause of death (14; 61%), followed by sudden cardiac death (3; 13%) and non-cardiovascular death (3; 13%). For 3 (13%) patients the cause of death remained unknown. Long-term HTx-free survival was significantly different among groups according to the pattern of disease onset, with the poorest outcome for HF patients, as shown in Figure 1 . On the other hand, at multivariable analysis, the independent predictors of long-term HTx-free survival were the left atrium enlargement and the presence of LV systolic dysfunction at enrolment ( Table 2) . The significant prognostic impact of LV dysfunction and left atrium dilatation at enrolment, regardless of the pattern of disease onset, is shown in Figure 2 .
The independent prognostic role of short-term clinical and echocardiographic revaluation is shown in Table 3 . The persistence of NYHA III-IV classes, the left atrium dilatation and the improvement or normality of LVEF at 6 months were selected as independent predictors of longterm outcome. As shown in Figure 3 , the short-term revaluation showed a significant incremental prognostic value when compared to the baseline evaluation (for overall HTx-free survival after 6 months, baseline model vs 6 months model: Area Under the Curve 0.79 vs 0.90, p=0.03).
During the long-term follow up 9 (11%) patients (7 for primary and 2 for secondary prevention) received an implantable cardioverter-defibrillator (ICD), with a mean interval of 101±112 [median 59; first-third quartile: ] months after the disease onset. Notably, all the 3 episodes of sudden death occurred when device therapy was not routinely used at our institution.
Predictors of Improvement/Normalization of Left Ventricular Ejection Fraction
At multivariable analysis, the presence of LV dysfunction at baseline was the only independent
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In the subgroup of patients with LV dysfunction at baseline, optimal medical therapy (with angiotensin-converting enzyme inhibitors and beta-blockers) was the only variable associated with 6 months improvement/normality of LVEF (OR 6.417, CI 1.081-34.861, p 0.031).
Fulminant Myocarditis
Out of the whole sample, 10 patients (12%) presented with fulminant myocarditis. Compared to the others, fulminant forms presented a more severe hemodynamic impairment at baseline and were more frequently treated with intravenous inotropes; moreover, fulminant patients were significantly younger, and 4 of them (40%) were younger than 13 (Table 4) . Histopathological analysis indentified lymphocytic myocarditis in 9 patients and eosinophilic myocarditis in one.
Five out of 10 patients with fulminant forms died or underwent HTx soon after the disease onset (Figure 4) . In particular, 4 among these patients accounted for all the events during the first 6 months follow-up in the whole population. All pediatric fulminant patients (age <13 years) met the study endpoint and in 3 cases diagnosis was obtained at autopsy.
After 6 months, patients surviving the acute phase presented clinical and echocardiographic features comparable to the others (Table 4 ) and demonstrated an excellent long-term survival free of HTx (Figure 4 ).
Discussion
The prompt management and early long-term prognostic stratification of patients with AM represent a challenging task for clinical cardiologists, as both clinical presentation and long term evolution may present great variability. In this regard, the clinical course of AM may be dramatic were more frequently treated with intravenous inotropes; moreover, fulminant p pa at atie e en nts s s we we were re re ignificantly younger, and 4 of them (40%) were younger than 13 (Table 4) . Histopathological an nal al alys ys ysis is is i i ind nd nden en ntifi fi fied ed ed lymphocytic myocarditis in 9 9 9 p patients and eo osi si s no oph ph phi il ilic myocarditis in one.
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and physicians face challenging decisions, such as early referral for HTx or prophylactic placement of an ICD.
Current data provide a valuable clinical insight in the patterns of presentation and evolution of AM and underline the relevance of tight revaluation for the appropriate clinical management of such patients. In particular, relevant findings of this study are: 1) the independent association between poor prognosis and left atrium enlargement and LV dysfunction at diagnosis of AM; 2) the incremental predictive power of short-term revaluation for long-term risk stratification; 3) the poor survival of the subgroup of patients with fulminant myocarditis.
Baseline evaluation
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Role of short-term re-evaluation
AM represents a model of possibly reversible myocardial disease. Early spontaneous LV function recovery has been previously described in 39% of patients with EMB-proven AM 16 , while significant early improvement of LV function has been demonstrated in 60% of patients with AM during immunosuppressive treatment 17 . In both series, LV function recovery was invariably associated with excellent mid-term prognosis.
In line with these results, early improvement or normality of LVEF was observed in 53%
of our patients at 6 months. In the high-risk subgroup of patients with LVEF<50%, medical therapy with angiotensin-converting enzyme inhibitors and beta-blockers was the only variable independently associated with LV function recovery. Interestingly, as previously reported 18 ,
immunosuppressive treatment was not associated with LVEF improvement or survival in our analysis. We assume that this finding may be confounded by earlier therapeutic strategies when immunosuppression was administered to all patients with AM regardless of LVEF and without the guidance of immunohistochemical 19 and virological analyses 20 .
Importantly, the prompt improvement or normality of LVEF was independently associated with long-term outcome on multivariable analysis, regardless of LV function at disease onset (Table 3) . Moreover, the short-term revaluation presented additional incremental predictive value when compared to the baseline evaluation, thus allowing a more accurate longterm risk stratification (Figure 3) . In particular it is worthy of note that patients experiencing an increase of LVEF by 20 percentage points or a LVEF 50% and a low NYHA functional class at 6 months demonstrated an excellent long-term prognosis.
Fulminant myocarditis
AM may abruptly present with severe HF rapidly progressing towards cardiogenic shock, ndependently associated with LV function recovery. Interestingly, as previously y re e epo po port rt ted ed ed 18 8 18 , , , mmunosuppressive treatment was not associated with LVEF improvement or survival in our an nal al alys ys ysis is is. We We We ass sum um ume e that this finding may be co o on nf nfo ounded by earl lie ie i r th h her er era a apeutic strategies when m mm mu munosuppre ress ss sio o on n w w was s s ad ad admi mi mini nist st ter er ered ed to o o all l p patie en nt ts w wi wit th th A A AM M M re re eg ga ard rdle le less s s o of f f LV LV L EF EF EF a a and nd nd w w wi it itho ho hou u ut h he e e gu gu guid id i an ance ce ce o of f im im immu muno no ohi hist sto oc oche he hemi mi mic ca cal l previously described as fulminant myocarditis 7, 14, 21 . In our sample this subgroup was characterized by extremely poor survival in the short term (Figure 4 ). These data are in contrast with the experience previously published by McCarthy et al 14 . However, different from this study, our sample includes pediatric patients and necroscopic diagnoses. On the other hand, our findings are in line with recent data from the Pediatric Health Information System database, which demonstrate a significant association between pediatric myocarditis with need of advanced circulatory support and severe prognosis 22 . The reasons for the high prevalence of the fulminant form in the pediatric population with AM and the causes of its poor outcome remain unknown. We hypothesize that disproportionate and uncontrolled immune response in children may explain at least partially the fulminant course.
Finally, consistently with previous reports 21 , patients that overcome the acute phase of the disease after 6 months presented clinical and echocardiographic features comparable to other patients (Table 4) and were characterized by an excellent long-term survival (Figure 4) .
Clinical implications
The fact that we observed only 82 AM over 28 years, despite the selection bias of a referral centre devoted to cardiomyopathies, might indicate either that AM is a rare disease, or, more reasonably, that it is often unrecognized. This could stem from different reasons. First, EMB remains the main tool to diagnose AM, although it presents well recognized accuracy limits, related to the number and sites of bioptic samples 23, 24 , proper timing of the procedure 25 and histopathological interpretation 26 . Consequently, the real incidence of suspected AM without criteria for EMB remains uncertain.
Our data indicate that AM patients with preserved LVEF at disease onset present a good long-term prognosis and should be treated conservatively. However, particular attention should may explain at least partially the fulminant course.
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The fact that t we we we o o obs bs bser er rve ve ved on on only l l 8 Conversely, patients presenting with chest pain (all biopsied during the early enrolment period of our study, representing a "historical" subgroup), were invariably characterized by preserved LVEF and excellent prognosis in the long-term follow-up. These data support the belief that EMB is not indicated in this subgroup of patients 27, 28 .
Finally, patients with remodeled left atrium and LV dysfunction at baseline represent a high risk subgroup and require frequent revaluations under optimal medical treatment in order to improve the prognostic stratification and guide a tailored global management (Figure 3 ). In this regard, patients showing a short-term improvement were characterized by benign long-term evolution. Accordingly, major clinical decisions such as referral for HTx or prophylactic ICD placement should be postponed and reconsidered, according to short-term evolution of clinical and instrumental parameters under optimal medical treatment.
Study Limitations and Distinctive Features
The study patients were enrolled in a tertiary referral centre for cardiomyopathies and HF, thus associated with a selection bias with respect to the characteristics of AM in the common clinical practice. Moreover, the patients were enrolled over a period of 28 years, during which several changes occurred in selection criteria for EMB, in EMB procedural protocols, in methods and techniques for biopsy evaluation as well as in criteria for administration of immunosuppressive therapy. Likewise, this period has been characterized by remarkable advances in the medical treatment of HF, LV dysfunction and arrhythmias. However, the historical phase of enrollment high risk subgroup and require frequent revaluations under optimal medical trea atm tm men en e t in in in o o ord rd rder er to mprove the prognostic stratification and guide a tailored global management (Figure 3) . In this e ega ga gard rd rd, , pa pa ati ti tien en nts s s sho ho howi w ng a short-term improveme me ment nt were characte e eri r r ze Moreover, data regarding CMR imaging and BNP testing were not included in the present analysis. Finally, given the relative small sample size and event-rate of this study, our registry can be perceived as hypothesis generating and further multicentre studies with larger samples are needed to confirm the present findings and validate the proposed multivariable model of clinical assessment. Nevertheless, to our knowledge, this is the largest sample of patients with EMBproven AM (according to Dallas criteria, excluding borderline myocarditis) described in literature with a homogeneous and average follow-up exceeding 12 years. In particular, the longterm follow-up provided valuable clinical insights on the evolution of such a variable disease.
Although a fair prognosis is consistent with the spontaneous or therapeutically-induced reversibility of the pathological substrate, AM may recur, evolve to dilated cardiomyopathy or complicate with life-threatening arrhythmias coherently with its complex and not yet fully understood pathophysiology 29 .
Conclusions
LV dysfunction at baseline evaluation defined a subgroup of patients characterized by poorer long-term prognosis in the setting of AM. On the other hand, the patterns of clinical presentation showed a weak prognostic power. Furthermore, the 6 months clinical/instrumental revaluation provided an incremental risk stratification with respect to the baseline assessment. In particular, early improvement/normality of LVEF was independently associated with a favorable long-term outcome. This study underscores the importance of clinical and echocardiographic early revaluation for the appropriate management of patients affected by a possibly reversible myocardial disease, such as AM.
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Conclusions s
Endomyocardial biopsy and sample analysis
Bioptic samples for histopathological analysis were fixed in 10% formaldehyde and then embedded in paraffin; multiple slices (5 micron thickness) were stained with hematoxylin-eosin, Azan Mallory 
